Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
7.24
+0.21 (2.99%)
At close: Apr 28, 2026, 4:00 PM EDT
7.24
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:11 PM EDT
Relmada Therapeutics Employees
Relmada Therapeutics had 17 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,375,598
Market Cap
759.39M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 17 | 0 | - |
| Dec 31, 2024 | 17 | -3 | -15.00% |
| Dec 31, 2023 | 20 | 6 | 42.86% |
| Dec 31, 2022 | 14 | 4 | 40.00% |
| Dec 31, 2021 | 10 | -4 | -28.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Allogene Therapeutics | 152 |
| Solid Biosciences | 121 |
| Alpha Tau Medical | 121 |
| Cullinan Therapeutics | 109 |
| BridgeBio Oncology Therapeutics | 92 |
| Lexicon Pharmaceuticals | 81 |
| Vor Biopharma | 76 |
| Design Therapeutics | 54 |
RLMD News
- 5 weeks ago - Relmada Therapeutics Earnings Call Transcript: Q4 2025 - Transcripts
- 5 weeks ago - Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026 - GlobeNewsWire
- 7 weeks ago - Relmada Therapeutics Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing - GlobeNewsWire
- 7 weeks ago - Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer - GlobeNewsWire
- 3 months ago - Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications - GlobeNewsWire